首页> 外文期刊>Reproductive sciences >Analysis of Clusterin and Clusterin Receptors in the Endometrium and Clusterin Levels in Cervical Mucus of Endometriosis
【24h】

Analysis of Clusterin and Clusterin Receptors in the Endometrium and Clusterin Levels in Cervical Mucus of Endometriosis

机译:子宫内膜异位症子宫颈内膜中Clusterin和Clusterin受体的分析及子宫颈粘液中Clusterin的水平

获取原文
获取原文并翻译 | 示例
       

摘要

Clusterin (CLU) is expressed in tissues and body fluids and is altered in some pathologies. In endometriosis, a noninvasive test is still lacking, thus, we analyzed CLU in mucus samples of patients. Additionally, we investigated localization of CLU and the putative CLU receptors (apolipoprotein E receptor 2 [ApoER2], megalin, very low-density lipoprotein receptor [VLDLR], and transforming growth factor receptor type I and II [TR1/TR2]). In mucus samples, CLU levels are modestly, but not significantly, higher in cases with endometriosis compared to cases without endometriosis, however, CLU levels are significantly (P = .02) reduced in patients with endometriosis receiving contraception compared to cases with endometriosis without contraception. Analysis of CLU and CLU receptors showed CLU mainly in the uterine epithelial cells in the majority of glands, but also in endothelial cells. Similarly, ApoER2 and TR1 could also be found preferentially in the endometrial glands. Whereas ApoER2 staining was strong in the vessels, TR1 was modestly expressed in vessels and muscle cells. In contrast, staining of VLDLR and TR2 was modest in the glands but stronger in vessels and muscle cells. Megalin staining was faint in the glands. A similar pattern for these proteins could be observed in adenomyosis. We demonstrate for the first time high concentrations of CLU in mucus samples and significantly reduced CLU levels in cases with endometriosis receiving contraception compared to cases with endometriosis without contraception. Furthermore, we identified uterine epithelial and endothelial cells as the main source of CLU and found different preferential CLU receptor complexes on glands, vessels, and smooth muscle cells.
机译:簇蛋白(CLU)在组织和体液中表达,并在某些病理中改变。在子宫内膜异位症中,仍然缺乏无创检查,因此,我们分析了患者粘液样本中的CLU。此外,我们研究了CLU和推定的CLU受体(载脂蛋白E受体2 [ApoER2],巨蛋白,极低密度脂蛋白受体[VLDLR]和转化生长因子受体I和II型[TR1 / TR2])的定位。在粘液样本中,子宫内膜异位患者的CLU水平适度但不显着高于无子宫内膜异位的患者,但是,与未接受避孕的子宫内膜异位患者相比,接受避孕的子宫内膜异位患者的CLU水平显着降低(P = .02) 。对CLU和CLU受体的分析显示,CLU主要存在于大多数腺体的子宫上皮细胞中,但也存在于内皮细胞中。同样,ApoER2和TR1也可能优先在内膜腺体中发现。尽管ApoER2染色在血管中很强,但TR1在血管和肌肉细胞中却适度表达。相反,VLDLR和TR2的染色在腺体中不明显,但在血管和肌肉细胞中则更强。 Megalin染色在腺体上微弱。在子宫腺肌病中可以观察到这些蛋白质的相似模式。我们首次证明,与没有避孕的子宫内膜异位症相比,接受避孕的子宫内膜异位症患者粘液样本中的CLU浓度高,并且CLU水平明显降低。此外,我们确定子宫上皮和内皮细胞是CLU的主要来源,并在腺体,血管和平滑肌细胞上发现了不同的优先CLU受体复合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号